Abstracts tagged "hypertension"

Abstract Number: 1635 • 2014 ACR/ARHP Annual Meeting
Association Between Carrying at Least One Apolipoprotein1 Variant Allele and Hypertension in Lupus Patients with Normal Renal Function
Ashira Blazer¹, H. Michael Belmont², Robert Clancy³, Peter M. Izmirly⁴ and Jill P. Buyon⁵, ¹Division of Rheumatology, NYU School of Medicine, New York, NY, ²NYU School of Medicine, New York, NY, ³Rheumatology, NYU Medical Center, New York, NY, ⁴Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁵Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose The apolipoprotein1 (APOL1) gene encodes a 3 domain protein found both in serum and intracellularly in endothelial cells among other cell types. Variant APOL1…
Abstract Number: 1500 • 2014 ACR/ARHP Annual Meeting
Preclinical and Clinical Characterization of MK-8457, a Selective Spleen Tyrosine Kinase and Zeta-Chain-Associated Protein Kinase 70 Inhibitor, in Normotensive and Hypertensive Cardiovascular Models
Hani Houshyar¹, Alan Bass², Judith Boice³, Michael Ellis⁴, Patrick Fanelli⁵, Tomoko Freshwater⁶, Jane Guo⁷, Kimberly Hoagland⁵, Janet Kerr⁵, Alan Northrup⁴, Mathew Maddess⁸, Richard Miller⁹, Marcella Ruddy¹⁰, Stella Vincent¹¹, Jayanthi Wolf⁵, Haoling Weng³, Gloria Zingaro⁵ and Gene Marcantonio³, ¹33 Avenue Louis Pasteur, Merck & Co., Boston, MA, ²Safety Assessment, Merck & Co., Boston, MA, ³Merck & Co., Whitehouse Station, NJ, ⁴Medicinal Chemistry, Merck & Co., Boston, MA, ⁵Merck & Co., West Point, PA, ⁶PPDM Early Stage, Merck & Co., Rahway, NJ, ⁷Immunology, Merck & Co., Boston, MA, ⁸Discovery Process Chemistry, Merck & Co., Boston, MA, ⁹Biochemistry & Biophysics, Merck & Co., Boston, MA, ¹⁰Merck & Co., Boston, MA, ¹¹PPDM Preclinical ADME, Merck & Co., Boston, MA
Background/Purpose: Spleen Tyrosine Kinase (SYK) and Zeta-chain-associated protein kinase 70 (ZAP70) are non-receptor protein kinases that bind phosophorylated receptor tyrosine-based activation motifs, critical in immune…
Abstract Number: 2593 • 2013 ACR/ARHP Annual Meeting
The Prognosis Of Scleroderma Renal Crisis In RNA-Polymerase III Antibody (ARA) Positive Compared To ARA Negative Patients
Bernadette Lynch¹, Henry Penn², Jennifer Harvey³, Aine Burns⁴ and Christopher P. Denton⁵, ¹Department of Rheumatology, The Royal Free Hospital, London, United Kingdom, ²Northwick Park Hospital, Harrow, United Kingdom, ³Clinical Immunology, Royal Free Hospital, London, United Kingdom, ⁴Department of Nephrology, The Royal Free Hospital, London, United Kingdom, ⁵Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom
Background/Purpose: Scleroderma renal crisis (SRC) usually presenting with accelerated hypertension and acute kidney injury (AKI) is one of the most severe complications of Systemic Sclerosis…
Abstract Number: 2103 • 2013 ACR/ARHP Annual Meeting
Relationships Between Self-Efficacy, Outcome Expectancy, and Outcomes In Older Adults With Osteoarthritis Of The Knee and Hypertension: Baseline Results
Elizabeth A. Schlenk¹, Deborah Crowley-Lisowski¹, Sarah Twerski¹, Alice Fallon¹, Alyssa Sartore¹, Susan Sereika¹, Joan Rogers², G. Kelley Fitzgerald³ and C. Kent Kwoh⁴, ¹School of Nursing, University of Pittsburgh, Pittsburgh, PA, ²School of Health and Rehabilitation Sciences, Occupational Therapy, University of Pittsburgh, Pittsburgh, PA, ³School of Health and Rehabilitation Sciences, Physical Therapy, University of Pittsburgh, Pittsburgh, PA, ⁴School of Medicine, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Staying Active with Arthritis (STAR), an intervention guided by Bandura’s Self-Efficacy Theory, is being investigated in an ongoing clinical trial of an individually delivered,…
Abstract Number: 2263 • 2012 ACR/ARHP Annual Meeting
The Association Between Prior Pregnancy Morbidity and Cardiovascular Events in Women with Systemic Lupus Erythematosus
Megan E. B. Clowse¹, Eliza F. Chakarvarty², Jill P. Buyon³ and Gerald McGwin Jr.⁴, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, CA, ³Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Adverse pregnancy outcomes have been associated with increased cardiovascular disease in healthy women. We hypothesized that women with SLE and a history of adverse…
Abstract Number: 1667 • 2012 ACR/ARHP Annual Meeting
Impact of Rheumatoid Arthritis On Recognition of Hypertension in a Medically Homed Population
Christie M. Bartels¹, Heather Johnson², Katya Voelker³, Patrick Mc Bride⁴ and Maureen Smith⁵, ¹Rheumatology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Cardiology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ³Univ of Wisconsin School of Medicine and Public Health, Madison, AA, ⁴Cardiology/Medicine, Univ of Wisconsin School of Medicine and Public Health, Madison, WI, ⁵Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI
Impact of Rheumatoid Arthritis on Recognition of Hypertension in a Medically Homed PopulationBackground/Purpose: Numerous studies report increased cardiovascular disease (CVD) events and others describe increased…
Abstract Number: 162 • 2012 ACR/ARHP Annual Meeting
Metabolic Syndrome: The Genesis of Nephrolithiasis in Gout Patients
Filipi M. Mello¹, Rafael B. Tomita², Ricardo Fuller³, Marco Antonio G. P. Filho², Thiago B. M. Barros⁴, Leandro L. do Prado², Kristopherson L. Augusto² and Claudia Goldenstein-Schainberg⁵, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Rheumatology Division - University of São Paulo, São Paulo, Brazil, ³Reumatologia, Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁴Rheumatology, Reumatologia Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Reumatologia, Rheumatology Division - University of São Paulo, São Paulo, Brazil
Background/Purpose: Gout patients have a high frequency of metabolic syndrome (MS), a disorder known to be associated with hyperinsulinemia. The latter condition augments proximal tubular…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].